|
CNBC'S MOST SHARED
- Apartment Vacancy Rate Hits 22-Year High
- Investing in Tech Now
- What You'll See On My NASCAR Documentary Tonight
- Warren Buffett's Complete Sun Valley CNBC Interview - Transcript and Video
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- Warren Buffett: Economy Needs Another Dose of Viagra
- Software Giants Rush to Cash In on Carbon-Trading
- Preparing for Retirement
- Cramer?s Outrage
- Playing by Different Rules
- Warren Buffett's Complete Sun Valley CNBC Interview - Transcript and Video
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- July 10th in Market History
- Microsoft Plays a Game of Bing Pong
- Options Smell 'Blood' on Infosys
- Christmas in July: Consumers To Out-Scrooge Scrooge
- GM's Second Chance
- Art Cashin: Traders Weigh Obama Policy Changes
- Warren Buffett: Economy Needs Another Dose of Viagra
- AIG Prepares to Pay More Bonuses to Executives
- China Demands Currency Reform, France Backs Debate
- UBS Can't Comply with US Request: Internal Memo
- Treasury Sold Warrants Below Market Value: Panel
- China Accuses Rio Staff of Bribing Steelmakers
- Assets Are Less Toxic, but Banks Have Other Troubles
- Chevron Says Q2 Hit by US Refining, Weak Dollar
- Stimulus Critics Put Obama, Democrats on Defensive
- Warren Buffett: Consumer Sales Remain 'Very, Very Soft'
RSS FEED

This morning Amylin Pharmaceuticals, Eli Lilly and Alkermes announced the highly anticipated test results on their once-a-week, Type 2 diabetes drug. One analyst recently called this the most important biotech data of the second half of this year. Many expect the drug to become a multi-billion dollar blockbuster.
AMLN and LLY are partners on the twice-a-day injectable diabetes drug Byetta. Over the past few weeks they started doing direct-to-consumer advertising for the first time. And in the last week I've noticed that the campaign has escalated from a very basic brand-awareness tone to a more pointed approach where they're even mentioning how much weight patients lost in clinical trials.
I'm assuming the FDA is cool with that, but it does make me wonder. Analysts have long talked about how they believe a lot of people who are not diabetic are going on Byetta just to help them shed pounds. That would be what's called "off-label use" and Amylin and Lilly are prohibited from promoting it as a diet drug. Anyway, I digress.
So, the companies say that the once-a-week Byetta resulted in a greater reduction in blood-sugar levels than was achieved in a mid-stage test and with twice-a-day Byetta. Three out of four patients got their blood-sugar level below the recommended benchmark. There was a 30% lower incidence of mild, transient nausea which is a common side-effect with twice-a-day Byetta.
However, on average patients lost about eight pounds. And because that's comparable to the weight loss seen with twice-a-day, investors seem to be disappointed and are selling shares of AMLN and ALKS as I write this, while LLY has been up and down. Alkermes makes the technology that allows the drug to last a week in the body and would receive a royalty on sales. LLY and AMLN would split the rest evenly.
![]() |
CNBC.com Byetta Needle |
Amylin execs were quick to point out that 90% of the 300 or so patients in the clinical trial finished the study. The once-a-week Byetta comes with a 23 gauge needle and Amylin officials say, "It was very well accepted."
![]() |
CNBC.com 23 Gauge Needle |
The companies are saving them for publication in a peer-reviewed medical journal which in the scientific and investor communities give drug data additional credibility. Today, though, investors don't seem to be assigning any.
Questions? Comments?



.ll_medium.jpg)




